Objective: Risk factors for the development of vasculopathy and malignancies as the most important causes of morbidity and mortality after heart transplantation are not well defined. Methods: Univariate and multivariate Cox regression analysis of the data derived from our 84 survivors of more than 3 months after orthotopic heart transplantation between 1984 and 1996. Measurement of carbonmonoxide-hemoglobin blood levels with an ABL 520 analyzer. Results: Recipient or donor age, the mode of immunosuppression, total-, LDL-and HDL-cholesterol, the HDL/LDL-ratio, triglycerides, hypertension, diabetes mellitus, CMV status and rejection episodes had no independent influence on total mortality or the occurrence of graft vasculopathy or cancer. By means of an intensive questionnaire (in case of deceased patients, by their relatives) and measurement of CO-Hb blood levels we detected a high rate of patients who smoked after transplantation (22/84 = 26%). Four patients confessed smoking after undergoing the blood test. Non-smokers were defined as denying it in the questionnaire and having CO-Mb levels < 2.5% in repeated measurements. All but one were smokers before heart transplantation.
Introduction
Heart transplantation (HTx) has become a standard procedure in cardiovascular surgery [13] . However, its success was limited by short-term complications such as infection or rejection and long-term problems such as ' Presented at the 10th Annual Meeting of the European Association of Cardio-thoracic Surgery, Prague, Czech Republic, 6-9 October 1996.
coronary artery vasculopathy and an enhanced cancer risk [14] . Improvements in outcome have largely been attributed to better management of early post-operative problems, however long-term mortality, M S%/year [8] , is relatively high and deserves investigational attention. Whereas infection or rejection can be detected and treated rather easy, the occurrence of vasculopathy and cancer seems to be unpredictable-and once diagnosed not sufficiently treatable.
In order to define risk factors for these long-term problems we evaluated 12 years follow-up data of our 84 surviving patients of more than 6 months, after orthotopic heart transplantation between 1984 and 1996.
Material and methods
Data were analyzed from the sheets of all 109 patients who received an orthotopic heart transplant at our center between 1984 and 1996. Twenty-five (23%) patients died in the first 6 months post-operatively due to primary graft failure: acute rejection or infection or were not followed up for at least 6 months during preparation of this paper. The remaining 84 long-term survivors were analyzed for parameters of possible prognostic power such as the classical cardiovascular risk factors, smoking, hyperlipidemia, diabetes mellitus and hypertension and risk factors which may be of particular importance after heart transplantation (CMV-status, allograft rejective activity). The preoperative CMV-status was assessed as CMV-IgG positivity, the post-operative CMV status was defined by repeated 3-monthly determinations of CMV-DNA in leukocytes. More than one positive result per patient was defined as CMV activity. Blood lipid values were determined by standard laboratory methods in 3-month intervals. All the values were averaged over the years to get an impression of the total lipid burden.
By means of an intensive questionnaire (in case of deceased patients, by their relatives) smoking habits were evaluated. Carbonmonoxide levels were routinely determined from arterial blood, stemming from cannulation of the radial artery during routine right heart catherization after yearly myocardial biopsies. Nonsmokers were defined as denying it in the questionnaire and having CO-Hb levels < 2.5% in repeated measurements. The presence of vasculopathy was defYined as a definite diagnosis of myocardial infarction, typical angiographic changes or autopsy results. Coronary events were defined as a definite diagnosis of myocardial infarction or a rhythmogenic event ultimately leading to death. Differences in the results were checked for significance by means of a Student's t-test for unmatched pairs. Nonparametric data were checked for significance with the Wilcoxon test. Survival rate was calculated with Kaplan-Meier analysis and differences between groups were tested for significance with the log-rank test or in a multivariate approach with Cox regression analysis.
Results
Smokers and non-smokers did not differ in baseline characteristics such as age, gender, underlying diseases and CMV-IgG positivity (Table 1) . Later smokers reported smoking pre HTx in a high rate (96%). shows the post-operative characteristics of smokers and non-smokers. Both groups were similar in body mass index, donor age, ischemic time of the donor heart, later pacemaker dependence, lipid values and rejective activity. However, they differed considerably in the presence of vasculopathy and malignancies. These complications leading to typical patterns in causes of death in both groups (Table 3) . Coronary conditions were negligible in non-smokers. In regard to tumors the exclusive development of lung cancer (n = 5/6) in the smoking cohort was evident. The other malignancy was an oropharyngeal carcinoma which is also known to be associated with smoking. All malignancies in the nonsmoking group were lymphomas which are typical com- Total n = 84 survivors of more than 6 months. (Table 4) . When survival was analyzed, preand post-operative smokers were found to have a significantly worse prognosis than non-smokers (Figs. 1 and 2). Smoking correlates very closely to blood levels of carboxy-monoxide. When patients were grouped according to carboxy-hemoglobin cutoff level of 2.5%, curves were very similar to survival of smokers and non-smokers. Above a CO-Hb level of 2.5% no patient survived after 4 years of observation (mortality 100%) vs. 51% of the patients with lower values were still alive and well after 10 years (Fig. 3) . The group of quitters (n = 26) was also analyzed in regard to cause of death. In this group 4 patients died. Reasons for death were: Burkitt-Lymphoma, n = 1; infection, n = 1; rejection, n = 2. In another patient of this group a bronchial carcinoma was recently diagnosed and treated with radiation therapy.
Discussion
Our findings confirm the well known hazards of smoking in a high risk cohort. Whereas in a normal population about half of all regular cigarette smokers will be killed by their habit [2] nearly all will be killed after heart transplantation and immunosuppression (Table 3 , Fig. 3 ). Smoking dramatically potentiates morbidity and mortality following HTx.
In our cohort, smoking seems to be much more important than other classical risk factors, especially blood lipid [17] . Heart transplantation is not the only surgical measure whose benefits were offset by smoking. In particular, patients who smoke after bypass surgery had a worse prognosis (survival 68% vs. 84% after 10 years as compared to non-smokers) [l] . Similar data are available from patients after myocardial infarction. Persistent smokers had a 31% 4-year mortality as compared to 17% in non-smokers [7] .
Several mechanisms have described how tobacco use can alter cardiac function. Besides a direct stimulation of arteriosclerosis [l I] coronary vasoconstriction by an impairment of endothelium-dependent arterial vasodilator function is most important [19] . An increase of myocardial oxygen consumption [4] and a stimulation of thrombin generation [9] are further mechanisms. Especially, diastolic cardiac function may be disturbed [12] . Maybe a combination of these factors can play an important role. Further investigation is required to clarify all questions. In regard to the obviously increased risk of lung cancer an interaction of immunosuppression with the smoking-induced mutation of the ~53 tumor suppressor gene is discussed [lo] . Work is in progress to detect p53 in our lung cancer specimens. Lipid peroxidation may be another plausible mechanism because anti-oxidative capacity in HTx patients is exhausted in the first perioperative phase [16] . Based on our data we speculate that hidden or overt smoking may contribute to mortality after heart transplantation in other centers. Knowing our alarming data, every effort should be undertaken to detect and wean smokers before and after orthotopic heart transplantation. In our cohort every patient but one stopped smoking when survival curves were explained to them. Former smokers should be carefully watched because up to 40% start smoking again some time after transplantation, despite clear advise not to do so. Detection of smoker's pre and post HTx may be limited by patients non-compliance to full exploration [18] . In our cohort 5 of 22 smokers only confessed smoking when confronted with the carboxy-hemoglobin data. Therefore, we suggest that routine measurements of CO-Hb (the most sensitive) or another marker of tobacco use such as cotinine should be included in every follow-up program after heart transplantation [3] . When smoking was reported or detected transdermal or oral nicotine applications may be a feasible approach for its cessation [6] .
In the light of our data it should be discussed whether smokers should be allowed such an expensive and complex therapy as heart transplantation at all. We feel that a half year abstinence with repeatedly negative CO-Hb levels should be a prerequisite for listing. Because of their high risk of smoking relapse, former smokers eventually should undergo chemoprophylactic measures such as vitamin A or E application [5] .
